Moreover, three JAK inhibitor-resistant mutants were identified in B-cell acute lymphoblastic leukemia, and in vivo results demonstrated that HSP90 inhibition by AUY922 and 17-AAG targeted JAK2 and overcame resistance to enzymatic kinase inhibitors including BVB808, a novel JAK2 inhibitor of the N-aryl-pyrrolopyrimidine scaffold class [46]. The gene discussed is JAK2; the disease is B-cell acute lymphoblastic leukemia.